Cat. #153506
Anti-EGFR [225]
Cat. #: 153506
Sub-type: Primary antibody
Unit size: 100 ug
Target: Epidermal Growth Factor Receptor
Class: Monoclonal
Reactivity: Human
Host: Mouse
This fee is applicable only for non-profit organisations. If you are a for-profit organisation or a researcher working on commercially-sponsored academic research, you will need to contact our licensing team for a commercial use license.
Contributor
Institute: Clonegene LLC
Tool Details
*FOR RESEARCH USE ONLY (for other uses, please contact the licensing team)
- Name: Anti-EGFR [225]
- Alternate name: EGFR, ErbB-1, HER1
- Research fields: Cell signaling and signal transduction
- Clone: 225
- Tool sub type: Primary antibody
- Class: Monoclonal
- Conjugation: Unconjugated
- Reactivity: Human
- Host: Mouse
- Description: Mutations that lead to EGFR overexpression (known as upregulation) or overactivity have been associated with a number of cancers, including squamous-cell carcinoma of the lung, anal cancers, glioblastoma and epithelial tumors of the head and neck. These somatic mutations involving EGFR lead to its constant activation, which produces uncontrolled cell division. In glioblastoma a more or less specific mutation of EGFR, called EGFRvIII is often observed. Mutations, amplifications or misregulations of EGFR or family members are implicated in about 30% of all epithelial cancers. Monoclonal 225 is a classic reagent in tumor therapy with more than 100 published references. The human/mouse chimeric antibody known as Cetuximab was derived from this monoclonal antibody.
- Isotype: IgG1
Target Details
- Target: Epidermal Growth Factor Receptor
- Target background: Mutations that lead to EGFR overexpression (known as upregulation) or overactivity have been associated with a number of cancers, including squamous-cell carcinoma of the lung, anal cancers, glioblastoma and epithelial tumors of the head and neck. These somatic mutations involving EGFR lead to its constant activation, which produces uncontrolled cell division. In glioblastoma a more or less specific mutation of EGFR, called EGFRvIII is often observed. Mutations, amplifications or misregulations of EGFR or family members are implicated in about 30% of all epithelial cancers. Monoclonal 225 is a classic reagent in tumor therapy with more than 100 published references. The human/mouse chimeric antibody known as Cetuximab was derived from this monoclonal antibody.
Handling
- Format: Liquid
- Unit size: 100 ug
- Shipping conditions: Shipping at 4° C
